Zymeworks Inc. (ZYME) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.81B USD. 52-week range 16.00 to 31.34 USD. Data as of 2026-10-09.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a ...